Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SPR | P35270 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769162 | 0.93 | GPR119 (0.57) | GPR119EPHX2ALDH1A1HTTSPR | |
| SCHEMBL30193463 | 0.93 | GPR119 (0.57) | GPR119EPHX2ALDH1A1HTTSPR | |
| SCHEMBL7242563 | 0.93 | GPR119 (0.57) | GPR119EPHX2ALDH1A1HTTSPR | |
| SCHEMBL6306297 | 0.88 | GPR119 (0.53) | GPR119EPHX2SPRUSP30 | |
| SCHEMBL29548089 | 0.88 | GPR119 (0.53) | GPR119EPHX2SPRUSP30 | |
| SCHEMBL6305698 | 0.86 | GPR119 (0.53) | GPR119ALDH1A1HTTSPRUSP30 | |
| SCHEMBL4713304 | 0.85 | GPR119 (0.62) | GPR119EPHX2KDM1AUSP30 | |
| SCHEMBL20764852 | 0.85 | GPR119 (0.56) | GPR119 | |
| SCHEMBL5268593 | 0.84 | GPR119 (0.65) | GPR119EPHX2ALDH1A1KDM1AUSP30 | |
| Hydrochloric Acid SCHEMBL7527771 | 0.84 | GPR119 (0.49) | GPR119EPHX2KDM1ACCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| EP-3672959-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2002055541-A2 | PEPTIDES HAVING INHIBITING ACTIVITY ON THE PRODUCTION OF NITRIC OXIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-18 | — | — | WO | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | GPR119 620/4885EPHX2 1642/4885ALDH1A1 947/4885 |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, TPMT, HTR7 | GPR119 2332/4885EPHX2 806/4885ALDH1A1 2144/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | GPR119 447/4885EPHX2 1256/4885ALDH1A1 3228/4885 |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | GPR119 2038/4885EPHX2 1309/4885ALDH1A1 3285/4885 |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | GPR119 620/4885EPHX2 1642/4885ALDH1A1 947/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GPR119 136/4885EPHX2 703/4885ALDH1A1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.